U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C28H29BrN4O3
Molecular Weight 549.459
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of UCB-1184197

SMILES

CCOC(=O)[C@H](CC1=CC=C(NC2=C3C=NC=CC3=CC=N2)C=C1)NC4=C(Br)C(=O)C45CCCCC5

InChI

InChIKey=QCYAXXZCQKMTMO-QFIPXVFZSA-N
InChI=1S/C28H29BrN4O3/c1-2-36-27(35)22(33-24-23(29)25(34)28(24)12-4-3-5-13-28)16-18-6-8-20(9-7-18)32-26-21-17-30-14-10-19(21)11-15-31-26/h6-11,14-15,17,22,33H,2-5,12-13,16H2,1H3,(H,31,32)/t22-/m0/s1

HIDE SMILES / InChI

Molecular Formula C28H29BrN4O3
Molecular Weight 549.459
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including http://www.ingentaconnect.com/content/ben/cir/2012/00000008/00000002/art00004?crawler=true | https://www.ncbi.nlm.nih.gov/pubmed/24179032

Zaurategrast (CDP323) is an ethyl ester prodrug of CT7758, a potent carboxylic acid antagonist of integrin alpha4-beta1 (α4β1) or very late antigen 4 (VLA4). CDP323 was under development with UCB and Biogen Idec for the treatment of multiple sclerosis. Its development was discontinued in 2009 based on inadequate interim efficacy data in a phase II clinical trial.

Approval Year

AUC

AUC

ValueDoseCo-administeredAnalytePopulation
0.5 μg × h/mL
500 mg/kg single, oral
dose: 500 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZAURATEGRAST plasma
Mus musculus
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1000 mg 2 times / day multiple, oral
Highest studied dose
Dose: 1000 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1000 mg, 2 times / day
Sources: Page: p.7, 8
unhealthy, ADULT
n = 14
Health Status: unhealthy
Condition: multiple sclerosis
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 14
Sources: Page: p.7, 8
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Other InhibitorOther SubstrateOther Inducer


Drug as perpetrator​

Drug as perpetrator​

Drug as victim

Drug as victim

PubMed

PubMed

TitleDatePubMed
Pharmacodynamic consequences of administration of VLA-4 antagonist CDP323 to multiple sclerosis subjects: a randomized, double-blind phase 1/2 study.
2013
In vitro hydrolysis and transesterification of CDP323, an α4β1/α4β7 integrin antagonist ester prodrug.
2014 Jan
Patents

Patents

Sample Use Guides

Multiple sclerosis subjects were randomized to 28-day treatment with Zaurategrast (CDP323) 100 mg twice daily (bid), 500 mg bid, 1000 mg once daily (qd), 1000 mg bid, or placebo. CDP323 at daily doses of 1000 or 2000 mg induced significant increases in total lymphocyte count and suppressed VCAM-1 binding by reducing unbound very late antigen-4 expression on lymphocytes.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Sat Dec 16 02:16:52 GMT 2023
Edited
by admin
on Sat Dec 16 02:16:52 GMT 2023
Record UNII
9A54BAZ0YA
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
UCB-1184197
Code English
CDP-323
Code English
ZAURATEGRAST ETHYL ESTER
Common Name English
CDP323
Code English
L-PHENYLALANINE, N-(2-BROMO-3-OXOSPIRO(3.5)NON-1-EN-1-YL)-4-(2,7-NAPHTHYRIDIN-1-YLAMINO)-, ETHYL ESTER
Common Name English
Code System Code Type Description
DRUG BANK
DB05092
Created by admin on Sat Dec 16 02:16:52 GMT 2023 , Edited by admin on Sat Dec 16 02:16:52 GMT 2023
PRIMARY
EPA CompTox
DTXSID30196546
Created by admin on Sat Dec 16 02:16:52 GMT 2023 , Edited by admin on Sat Dec 16 02:16:52 GMT 2023
PRIMARY
SMS_ID
300000044183
Created by admin on Sat Dec 16 02:16:52 GMT 2023 , Edited by admin on Sat Dec 16 02:16:52 GMT 2023
PRIMARY
CAS
455264-30-9
Created by admin on Sat Dec 16 02:16:52 GMT 2023 , Edited by admin on Sat Dec 16 02:16:52 GMT 2023
PRIMARY
FDA UNII
9A54BAZ0YA
Created by admin on Sat Dec 16 02:16:52 GMT 2023 , Edited by admin on Sat Dec 16 02:16:52 GMT 2023
PRIMARY
PUBCHEM
23394557
Created by admin on Sat Dec 16 02:16:52 GMT 2023 , Edited by admin on Sat Dec 16 02:16:52 GMT 2023
PRIMARY
Related Record Type Details
METABOLITE ACTIVE -> PRODRUG
Related Record Type Details
ACTIVE MOIETY